JP2007517016A - 低溶解性薬剤及びポロキサマーの固体組成物 - Google Patents

低溶解性薬剤及びポロキサマーの固体組成物 Download PDF

Info

Publication number
JP2007517016A
JP2007517016A JP2006546397A JP2006546397A JP2007517016A JP 2007517016 A JP2007517016 A JP 2007517016A JP 2006546397 A JP2006546397 A JP 2006546397A JP 2006546397 A JP2006546397 A JP 2006546397A JP 2007517016 A JP2007517016 A JP 2007517016A
Authority
JP
Japan
Prior art keywords
drug
poloxamer
concentration
composition
solid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006546397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517016A5 (cg-RX-API-DMAC7.html
Inventor
ダニエル・トッド・スミジー
ウォリン・ケニヨン・ミラー
ドウェイン・トマス・フリーゼン
ウォルター・クリスティアン・バブコック
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2007517016A publication Critical patent/JP2007517016A/ja
Publication of JP2007517016A5 publication Critical patent/JP2007517016A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006546397A 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物 Abandoned JP2007517016A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53383603P 2003-12-31 2003-12-31
PCT/IB2004/004287 WO2005065657A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Publications (2)

Publication Number Publication Date
JP2007517016A true JP2007517016A (ja) 2007-06-28
JP2007517016A5 JP2007517016A5 (cg-RX-API-DMAC7.html) 2008-02-14

Family

ID=34748969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546397A Abandoned JP2007517016A (ja) 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物

Country Status (6)

Country Link
US (1) US8974823B2 (cg-RX-API-DMAC7.html)
EP (1) EP1701704A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007517016A (cg-RX-API-DMAC7.html)
BR (1) BRPI0418330A (cg-RX-API-DMAC7.html)
CA (1) CA2548376A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005065657A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510138A (ja) * 2005-10-04 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態
JP2014500869A (ja) * 2010-11-09 2014-01-16 エフ.ホフマン−ラ ロシュ アーゲー Hcv感染症を処置するための医薬組成物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2142178B1 (en) * 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
JP2014532658A (ja) * 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JP5946798B2 (ja) * 2013-06-18 2016-07-06 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
JP5934677B2 (ja) * 2013-06-18 2016-06-15 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6010060B2 (ja) * 2014-02-21 2016-10-19 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
RU2639819C2 (ru) * 2014-12-30 2017-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Композиция, ингибирующая теломеразу
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DK0996429T3 (da) 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
AU4797999A (en) 1998-07-22 2000-02-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble nsaids
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
JP2004500358A (ja) 1999-12-08 2004-01-08 ファルマシア コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
KR100806412B1 (ko) 2000-01-28 2008-02-21 스미스클라인 비참 코포레이션 전기방사 약제학적 조성물
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
DE10038571A1 (de) 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
KR20020014570A (ko) 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
CZ20033211A3 (cs) * 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003214387A1 (en) * 2002-03-07 2003-09-16 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510138A (ja) * 2005-10-04 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態
JP2014500869A (ja) * 2010-11-09 2014-01-16 エフ.ホフマン−ラ ロシュ アーゲー Hcv感染症を処置するための医薬組成物

Also Published As

Publication number Publication date
WO2005065657A3 (en) 2006-06-22
BRPI0418330A (pt) 2007-05-02
CA2548376A1 (en) 2005-07-21
US20070141143A1 (en) 2007-06-21
US8974823B2 (en) 2015-03-10
WO2005065657A2 (en) 2005-07-21
EP1701704A2 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
US8974823B2 (en) Solid compositions of low-solubility drugs and poloxamers
Huang et al. Effects of the preparation process on the properties of amorphous solid dispersions
JP4065640B2 (ja) 医薬用固体分散物
EP1653928B1 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
KR100664822B1 (ko) 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
JP2984661B2 (ja) 噴霧乾燥固体分散系を含む組成物
US8491933B2 (en) Pharmaceutical compositions of semi-ordered drugs and polymers
KR20150082203A (ko) 엔잘루타마이드 제제
ZA200600853B (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
EP1701703B1 (en) Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
CN105722392B (zh) 非核苷逆转录酶抑制剂的组合物
MXPA06007625A (en) Solid compositions of low-solubility drugs and poloxamers
HK40119846A (en) Oral dosage forms of elraglusib
MXPA00001463A (en) Pharmaceutical solid dispersions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071220

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080502